Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer's Disease-Associated Antigens
Halberd Corporation (OTC PINK:HALB) has developed a novel method for extricating Alzheimer's Disease-related proteins from Cerebral Spinal Fluid (CSF) using gold-coated iron oxide nanoparticles.
This technique aims to combat neurofibrillary tangles linked to Alzheimer's Disease, with initial tests planned at Youngstown State University using E.coli. The company is advancing towards animal safety tests, focusing on eradicating harmful antigens from CSF to potentially slow the disease's progression. The projected increase in Alzheimer's cases reinforces the significance of this research.
- Successfully conjugated antibodies with gold-coated iron oxide nanoparticles.
- Unique method targets Alzheimer's-related proteins in CSF.
- Initial proof-of-concept testing underway at Youngstown State University.
- Plans for animal testing to confirm safety and efficacy.
- Addresses a growing global health concern with Alzheimer's projected to affect 14 million Americans by 2050.
- None.
Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy
JACKSON CENTER, PA / ACCESSWIRE / June 16, 2021 / Halberd Corporation (OTC PINK:HALB) has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process. These three antigens, which are found in Cerebral Spinal Fluid (CSF), are associated with the formation of neurofibrillary tangles concomitant with Alzheimer's Disease. Conjugation of these antibodies with gold-coated iron oxide particles provides the basis for the extracorporeal removal and eradication of these Alzheimer's Disease-associated peptides and proteins from Cerebral Spinal Fluid (CSF) through exposure to tuned radio frequency energy and/or laser emissive energy.
Dr. Shawn Q. Chen and his team at GreenBioAz, an Arizona State University incubator company are spearheading this research.
Dr. Mitchell S. Felder, Halberd's Chief Technical Officer, and a board certified attending Neurologist, stated, "There are numerous medical articles which indicate a correlation between the formation of neurofibrillary tangles and amyloid plaques in the onset and progression of Alzheimer's Disease. Three main constituents identified as leading to neuropathological changes in Alzheimer's Disease are Phosphorylated Tau, Tau, and Beta Amyloid. We believe that if we can eliminate sufficient quantities of these compounds from CSF then we can slow or arrest the development of neurofibrillary tangles and amyloid plaques, and therefore, the progression of Alzheimer's Disease."
William A. Hartman, Halberd's Chairman, President & CEO, commented, "Alzheimer's Disease affects more than six million people in the United States and as many as 40 million people worldwide, and these numbers are only projected to get worse. By 2050, it is estimated that as many as 14 million Americans over the age of 65 could be suffering from some degree of Alzheimer's. We believe that we are uniquely positioned to counter this trend through our patented extracorporeal method of capturing the offending constituents in CSF at the cellular level and safely and efficiently destroying them through exposure to tuned radio waves or alternatively, laser energy. Both such processes are covered by our patented and patent-pending technologies."
"We have now secured the necessary antibodies and antigens for our Alzheimer's Disease experimentation. We are in the process of completing preliminary proof-of-concept testing using E.coli as a surrogate at Youngstown State University (YSU). In addition, we have commenced planning animal tests. Animal tests are critical to demonstrate safety and efficacy of our process. Our number one focus is to the successful conclusion of the experimentation involving Alzheimer's Disease antigen elimination."
"As a team, we are extremely excited at the prospects of developing a successful treatment for this disease which has plagued untold numbers of people worldwide for centuries. This is truly revolutionary research and development."
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/651908/Halberd-Corporation-Successfully-Conjugates-Metallic-Particles-and-Antibodies-Against-Alzheimers-Disease-Associated-Antigens
FAQ
What breakthrough did Halberd Corporation achieve regarding Alzheimer's Disease?
What is the significance of the research conducted by Halberd Corporation?
Where is Halberd Corporation conducting its initial testing?
What is the expected impact of Halberd's method on Alzheimer's Disease progression?
What are the future plans for Halberd Corporation’s Alzheimer's research?
